title: Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging.
abstract: Amyloid PET imaging is a novel diagnostic test that can detect in living humans one of the two defining pathologic lesions of Alzheimer disease, amyloid-β deposition in the brain. The Amyloid Imaging Task Force of the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging previously published appropriate use criteria for amyloid PET as an important tool for increasing the certainty of a diagnosis of Alzheimer disease in specific patient populations. Here, the task force further clarifies and expands 3 topics discussed in the original paper: first, defining dementia experts and their use of proper documentation to demonstrate the medical necessity of an amyloid PET scan; second, identifying a specific subset of individuals with mild cognitive impairment for whom an amyloid PET scan is appropriate; and finally, developing educational programs to increase awareness of the amyloid PET appropriate use criteria and providing instructions on how this test should be used in the clinical decision-making process.
authors.affiliation: Departments of Radiology and Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Keith A
authors.initials: KA
authors.lastname: Johnson
authors.forename: Satoshi
authors.initials: S
authors.lastname: Minoshima
authors.forename: Nicolaas I
authors.initials: NI
authors.lastname: Bohnen
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Donohoe
authors.forename: Norman L
authors.initials: NL
authors.lastname: Foster
authors.forename: Peter
authors.initials: P
authors.lastname: Herscovitch
authors.forename: Jason H
authors.initials: JH
authors.lastname: Karlawish
authors.forename: Christopher C
authors.initials: CC
authors.lastname: Rowe
authors.forename: Saima
authors.initials: S
authors.lastname: Hedrick
authors.forename: Virginia
authors.initials: V
authors.lastname: Pappas
authors.forename: Maria C
authors.initials: MC
authors.lastname: Carrillo
authors.forename: Dean M
authors.initials: DM
authors.lastname: Hartley
mesh_terms: D000544:Alzheimer Disease / Q000000981:diagnostic imaging* / Q000209:etiology; D016229:Amyloid beta-Peptides / Q000032:analysis; D001921:Brain / Q000000981:diagnostic imaging*; D001923:Brain Chemistry; D015984:Causality; D057189:Checklist; D060825:Cognitive Dysfunction / Q000000981:diagnostic imaging* / Q000209:etiology; D003226:Congresses as Topic; D019468:Disease Management; D004502:Education, Medical, Continuing; D005194:Family Practice / Q000193:education; D005853:Geriatrics / Q000193:education; D006801:Humans; D009462:Neurology / Q000193:education; D010353:Patient Education as Topic; D058225:Plaque, Amyloid / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography / Q000592:standards*; D011361:Professional Competence; D012017:Referral and Consultation / Q000592:standards; D013664:Teaching Materials
chemical_list: D016229:Amyloid beta-Peptides